| - |
Prasugrel |
Efient® |
For the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention. |
Assessment Process Complete |
1st February 2010 |
 |
| - |
Pregabalin |
Lyrica® |
For the treatment of Generalised Anxiety Disorder. |
Full HTA Assessment |
15th December 2014 |
|
| - |
Pregabalin |
Lyrica® |
For the treatment of peripheral and central neuropathic pain, generalised anxiety disorder and as adjunctive therapy for epilepsy. |
Full HTA Assessment |
12th June 2015 |
|
| 25007 |
Progesterone |
Lubion® |
Progesterone (Lubion®) is indicated in adults for luteal support as part of an assisted reproductive technology (ART) treatment programme in infertile women who are unable to use or tolerate vaginal preparations. |
Rapid Review Complete |
7th March 2025 |
|
| - |
Progesterone (micronised) |
Utrogestan® |
Progesterone (micronised) is indicated in women for supplementation of the luteal phase during ART cycles. |
Rapid Review Complete |
20th November 2019 |
|
| - |
Prucalopride |
Resolor® |
For the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. |
Rapid Review Complete |
29th March 2011 |
|
| 24006 |
Quizartinib |
Vanflyta® |
Quizartinib is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia that is FLT3-ITD positive. |
Rapid Review Complete |
11th March 2025 |
|
| - |
Radium-223 |
Xofigo® |
For the treatment of adults with castration resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. It is for use in the hospital setting. |
Assessment Process Complete |
12th December 2014 |
|
| - |
Ramucirumab |
Cyramza® |
In combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction (GEJ) adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate. |
Assessment Process Complete |
26th July 2016 |
|
| - |
Ranolazine |
Ranexa® |
Cost-effectiveness of Ranolazine (Ranexa®) |
Rapid Review Complete |
19th November 2009 |
|
| 19054 |
Ravulizumab |
Ultomiris® |
For the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH): in patients with haemolysis with clinical symptom(s) indicative of high disease activity and in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. |
Assessment Process Complete |
30th May 2022 |
|
| 20036 |
Ravulizumab |
Ultomiris® |
Indicated in the treatment of patients with a body weight of 10 kg or above with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve, or have received eculizumab for at least 3 months and have evidence of response to eculizumab. |
Assessment Process Complete |
28th July 2022 |
|
| 25012 |
Ravulizumab |
Ultomiris® |
Ravulizumab (Ultomiris®) is indicated as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis who are anti-acetylcholine receptor antibody-positive. |
Rapid Review Complete |
12th March 2025 |
|
| 25013 |
Ravulizumab |
Ultomiris® |
Ravulizumab (Ultomiris®) is indicated for the treatment of adult patients with neuromyelitis optica spectrum disorder who are anti-aquaporin 4 antibody positive. |
Rapid Review Complete |
14th March 2025 |
|
| - |
Recombinant Human Parathyroid Hormone |
Natpar® |
Is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone. |
Rapid Review Complete |
21st May 2018 |
|
| - |
Regadenoson |
Rapiscan® |
Cost-effectiveness of Regadenoson (Rapiscan®) |
Rapid Review Complete |
2nd November 2011 |
|
| 21065 |
Regdanvimab |
RegkironaTM |
For the treatment of adults with coronavirus disease 2019 (COVID-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. |
Rapid Review Complete |
10th January 2022 |
|
| - |
Regorafenib |
Stivarga® |
For the treatment of patients with gastrointestinal stromal tumours (GIST) who have been previously treated with two tyrosine kinase inhibitors and have progressed or are intolerant to prior treatment with two TKI’s. |
Rapid Review Complete |
6th October 2014 |
|
| - |
Regorafenib |
Stivarga® |
For the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy. |
Assessment Process Complete |
1st July 2014 |
|
| 23017 |
Relugolix |
Orgovyx® |
Indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer. |
Rapid Review Complete |
14th March 2024 |
|
| 21055 |
Relugolix with estradiol and norethisterone acetate |
Ryeqo® |
Is indicated for moderate to severe symptoms of uterine fibroids in adult women of reproductive age. |
Rapid Review Complete |
3rd February 2022 |
|
| 24018 |
Relugolix with estradiol and norethisterone acetate |
Ryeqo® |
Relugolix with estradiol and norethisterone acetate (Ryeqo®) is Indicated in adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. |
Full HTA submission received from Applicant |
15th July 2025 |
|
| - |
Reslizumab |
Cinqaero® |
Is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment. |
Rapid Review Complete |
1st March 2017 |
|
| - |
Retigabine |
Trobalt® |
Cost-effectiveness of Retigabine (Trobalt®) |
Rapid Review Complete |
6th April 2011 |
|
| 24007 |
Rezafungin |
Rezzayo® |
Rezafungin (Rezzayo®) is indicated for the treatment of invasive candidiasis in adults. |
Rapid Review Complete |
11th March 2025 |
|
| - |
Ribociclib |
Kisqali® |
In combination with an aromatase inhibitor (AI) is indicated for the treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine based therapy. |
Assessment Process Complete |
13th August 2018 |
|
| - |
Ribociclib |
Kisqali® |
Is indicated in combination with an aromatase inhibitor or fulvestrant for the treatment of pre-, peri- and post-menopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine therapy, or in women who have received prior endocrine therapy: |
Rapid Review Complete |
11th July 2019 |
|
| 24045 |
Ribociclib |
Kisqali® |
Ribociclib in combination with an aromatase inhibitor (AI) is indicated for the adjuvant treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. |
Rapid Review Complete |
19th December 2024 |
|
| - |
Rifaximin |
Targaxan® |
Is indicated for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients ≥ 18 years of age. |
Rapid Review Complete |
7th August 2013 |
|
| - |
Rilpivirine |
Edurant® |
In combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml. |
Rapid Review Complete |
6th January 2012 |
|
| - |
Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF) |
Odefsey® |
For the treatment of adults and adolescents (≥ 12 years, body weight ≥35 kg) infected with HIV 1 without known mutations associated with resistance to the NNRTI class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV 1 RNA copies/ml. |
Rapid Review Complete |
13th July 2016 |
|
| 22051 |
Rimegepant |
Vydura® |
Rimegepant (Vydura®) for the treatment of acute migraine with or without aura and the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month. |
NCPE Assessment Process complete |
11th March 2025 |
|
| 22051 |
Rimegepant |
Vydura® |
For the acute treatment of migraine with or without aura in adults; and for the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month. |
NCPE Assessment Process Complete |
11th May 2025 |
|
| - |
Rimonabant |
Acomplia® |
For the management of multiple cardiovascular risks in overweight or obese patients in Ireland |
Assessment Process Complete |
16th October 2006 |
|
| - |
Riociguat |
Adempas® |
For the treatment of Pulmonary arterial hypertension (PAH) and Chronic thromboembolic pulmonary hypertension (CTEPH). |
Rapid Review Complete |
20th May 2014 |
|
| 23061 |
Risankizumab |
Skyrizi® |
Risankizumab is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. The Applicant is seeking reimbursement in a subgroup of the licensed population, as second-line treatment after failure of the first biologic therapy. |
NCPE Assessment Process Complete |
5th June 2024 |
|
| 22038 |
Risankizumab |
Skyrizi® |
Alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). |
Rapid Review Complete |
30th June 2022 |
|
| 24025 |
Risankizumab |
Skyrizi® |
For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional or biologic therapy. The Applicant is seeking reimbursement in a subgroup of the licensed population, as second-line treatment after failure of the first biologic therapy. |
Rapid Review Complete |
24th July 2025 |
|
| 19010 |
Risankizumab |
Skyrizi® |
Is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
Assessment Process Complete |
12th August 2021 |
|
| 21006 |
Risdiplam |
Evrysdi™ |
For the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. |
NCPE Assessment Process Complete |
20th October 2023 |
|
| 23071 |
Ritlecitinib |
Litfulo® |
For the treatment of severe alopecia areata in adults and adolescents 12 years of age and older. |
Full HTA submission received from Applicant |
11th February 2025 |
|
| - |
Rituximab |
MabThera® |
Is indicated in adults for Non-Hodgkin’s lymphoma (NHL): Is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy: As maintenance therapy for the treatment of follicular lymphoma patients responding to induction therapy: For the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. |
Rapid Review Complete |
24th September 2014 |
|
| - |
Rivaroxaban |
Xarelto® |
Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement. |
Rapid Review Complete |
22nd November 2017 |
|
| - |
Rivaroxaban |
Xarelto® |
For the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events. |
Assessment Process Complete |
18th June 2019 |
|
| - |
Rivaroxaban |
Xarelto® |
For the prevention of stroke in atrial fibrillation. |
Assessment Process Complete |
19th June 2012 |
|
| - |
Rivaroxaban |
Xarelto® |
For the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Total Hip Replacement or Total Knee Replacement. |
Full HTA Assessment |
18th September 2008 |
|
| - |
Rivaroxaban |
Xarelto® |
For the Treatment of Deep Vein Thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults. |
Assessment Process Complete |
24th February 2012 |
|
| - |
Rivaroxaban |
Xarelto® |
Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE. |
Rapid Review Complete |
22nd November 2017 |
|
| - |
Roflumilast |
Daxas® |
For the maintenance treatment of severe Chronic Obstructive Pulmonary Disease associated with chronic bronchitis in patients with a history of frequent exacerbations. |
Full HTA Assessment |
3rd November 2010 |
|
| - |
Rolapitant |
Varuby® |
For the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults. |
Rapid Review Complete |
13th June 2017 |
|
